Corbus Pharmaceuticals (CRBP)

Executive Summary

Corbus Pharmaceuticals is a clinical-stage biotech focused on oncology and obesity, with a pipeline including next-generation antibody-drug conjugates (ADCs) and small molecules. The company's lead asset, CRB-701 (a Nectin-4 targeting ADC), is in Phase 1/2 for solid tumors in combination with anti-PD-1. Additionally, CRB-601 (a novel immune checkpoint inhibitor targeting CD73) is being evaluated in Phase 1/2 for solid tumors. In obesity, CRB-913 (a peripherally restricted CB1 receptor inverse agonist) recently entered Phase 1 for obesity. Corbus has a history with lenabasum, which failed in Phase 3 for systemic sclerosis but provided insights. The company is now pivoting to these newer assets. Upcoming catalysts include initial data from CRB-913 obesity trial in mid-2026 and early efficacy readouts for CRB-601 and CRB-701 in late 2026. Corbus has a market cap around $190M, reflecting early-stage risk but potential upside if any of these programs succeed. Key risks include competition in oncology and obesity, and lack of late-stage data.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase 1 data for CRB-913 in obesity30% success
• Q4 2026Phase 1/2 interim data for CRB-601 in solid tumors25% success
• Q1 2027Phase 1/2 dose expansion data for CRB-701 in solid tumors30% success